Table 1 Clinical characteristics and peripheral blood NKT cell % of enrolled patients

From: Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients

Pt Age/Sex WHO class CG Baseline marrow blasts (%) IPSS Best response (time) 10 month response Clinical outcome (time) Baseline NKT (%) 10 month NKT (%)
 1 61/M MDS-U +21 1 1 CR (10 w) PD PD (10 m) 0.018 0.028
 2 69/M MDS del(5q) 2 0 TI (4 m) PD PD (10 m) 0.002 0.002
 3 71/M RCMD N 4 1 PD PD PD 0.001 0.000
 4 55/F RAEB-1 N 5 1 TI (4 m) PD PD (11 m) 0.231 0.250
 5 89/M MDS del(5q) 2 0 NA NA NA 0.000 NA
 6 77/F RAEB-1 del(5q) 7 1 TI, MCR (6 m) TI, MCR TI (17 m)a 0.001 0.001
 7 67/M MDS del(5q); t(2:11) 2 1 TI, CCR (4 m) TI, CCR TI, CCR (11 m)a 0.031 0.041
 8 66/M RCMD N 2 0.5 TI (4 m) SD SD (10 m)b 0.008 0.004
 9 56/M RAEB-1 N 6 1 CR (4 m) CR PD (15 m) 0.095 0.061
10 55/F RCMD N 1 1 CR (4 m) PD PD (10 m) 0.068 0.035
11 45/F RA N 1 0.5 CR (8 w) CR CR (26 m)a 0.001 0.001
12 46/F MDS del(5q) 0 0 CR (10 w) CR CR (27 m)a 0.802 1.671
13 51/F RAEB-1 del(5q) 8 1 CR (10 w) CR CR (11 m)a 0.098 0.053
  1. Abbreviations: CCR, complete cytogenetic response; CG, cytogenetics; CMR, complete marrow response; CR, complete remission; IPSS, International Prognostic Scoring System; MCR, marrow complete response; NA, not assessable; PD, progressive disease; Pt, patients; SD, stable disease; TI, transfusion independence.
  2. Time of best response and clinical progress are shown in weeks (w) or months (m).
  3. a Lenalidomide therapy ongoing.
  4. b Discontinued due to treatment related fatigue.
  5. NKT% indicates peripheral blood NKT cell levels as a proportion of CD3+ lymphocytes immediately before and after 10 months of lenalidomide therapy.